The Wall Street Transcript // June 1 .
PharmaMar completes patient recruitment of Phase III registration trial (ADMYRE) with APLIDIN® (plitidepsin) in multiple myeloma .
The pivotal study will assess the efficacy of plitidepsin plus dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma .
Madrid, June 1st, 2015 - PharmaMar announced today that the patient recruitment for the pivotal Phase III trial of APLIDIN® (plitidepsin) for the treatment of multiple myeloma, denominated ADMYRE, has been successfully completed. The study, which originally planned to include 250 patients, has enrolled 255 patients in 71 medical centers worldwide, including the US, Europe, Asia, South America, Australia, and New Zealand. An application for marketing authorization in Europe is planned to be submitted in 2016.
...